Eyepoint Pharmaceuticals Inc Earnings

The next earnings date for Eyepoint Pharmaceuticals Inc is October 29, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Eyepoint Pharmaceuticals Inc Earnings

Report DateEstimated Earnings Per Share
10/29/2025$-0.77

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Eyepoint Pharmaceuticals Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/06/2025---$-0.85-4.94%
07/30/2025---$0100.00%
05/06/2025Before Market$-0.65-58.54%
03/05/2025Before Market$-0.64-34.31%
11/08/2024Before Market$-0.541.82%
08/07/2024Before Market$-0.58-11.54%
05/08/2024Before Market$-0.55-30.95%
03/07/2024Before Market$-0.3332.65%
11/01/2023Before Market$-0.3335.29%
08/02/2023Before Market$-0.61-201.67%
05/03/2023Before Market$-0.5617.65%
03/02/2023Before Market$-1.16-90.16%
11/02/2022Before Market$-0.4930.00%
08/03/2022Before Market$-0.520.00%
05/04/2022Before Market$-0.563.45%
03/03/2022Before Market$-0.59-11.32%
11/03/2021Before Market$-0.58-45.00%
08/04/2021Before Market$-0.3518.60%
05/05/2021Before Market$-0.50-8.70%
03/04/2021Before Market$-1-488.24%
11/05/2020Before Market$-0.300.00%
08/05/2020Before Market$-14.76%
05/06/2020Before Market$-1.10-15.79%
03/05/2020Before Market$-113.79%
11/07/2019Before Market$-1.50-9.49%
08/07/2019Before Market$-1.108.33%
05/08/2019Before Market$-1.60-16.79%
03/14/2019Before Market$-1.2014.29%
11/06/2018Before Market$-1.90-29.25%
09/12/2018Before Market$-1.90-77.57%
05/08/2018After Market$-1.1015.38%
02/07/2018After Market$-0.1313.33%
11/07/2017Before Market$-1.500.00%
09/11/2017After Market$-1.60-6.67%
05/04/2017After Market$-1.500.00%
02/07/2017After Market$-0.0099.89%
11/07/2016After Market$-2.10-10.53%
09/12/2016After Market$-1.90-52.00%
05/05/2016After Market$-1.5023.08%
02/08/2016After Market$-1.80-20.00%
11/05/2015After Market$-1.70-17.24%
09/09/2015After Market$-1.70-25.93%
05/08/2015Before Market$-1.70-33.86%
02/05/2015After Market$-1.40-7.69%
11/07/2014Before Market$6.70658.33%
09/09/2014After Market$-1.403.45%
05/13/2014---$-0.8046.67%
02/07/2014---$-1.300.00%
11/12/2013---$-1.40-7.69%
09/25/2013---$-1.70-41.67%
05/13/2013---$-1.207.69%
02/06/2013---$-1.1015.38%
11/08/2012---$-1.10-10.00%
09/24/2012---$-1.1042.11%
05/09/2012---$-1.3025.71%
02/08/2012---$-1.3025.71%
11/07/2011---$-1.2042.86%
09/12/2011---$-0.1094.44%
05/10/2011---$-1.3039.53%
02/09/2011---$-1.50-133.33%
11/05/2010---$-1.70-17.24%
09/23/2010---$6.80---
05/12/2010---$-0.1592.29%
02/12/2010---$-0.01---
11/13/2009---$-0.87---
09/25/2009---$-0.29---
05/13/2009---$-0.35---
02/11/2009---$-0.48---
11/11/2008---$-0.26---

More About Eyepoint Pharmaceuticals Inc

Website
https://eyepointpharma.com
Country
USA
Full Time Employees
165

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

“Eyepoint Pharmaceuticals Inc Earnings” Can Refer to the Eyepoint Pharmaceuticals Inc Earnings Date

Some people say “Eyepoint Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Eyepoint Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Eyepoint Pharmaceuticals Inc Stock on the Earnings Date

If you own Eyepoint Pharmaceuticals Inc stock (EYPT) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Eyepoint Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Eyepoint Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Eyepoint Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Eyepoint Pharmaceuticals Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.